Implantable cardioverter defibrillator therapy for primary prevention of sudden cardiac death in the real world: Main findings from the French multicentre DAI-PP programme (pilot phase).

Arch Cardiovasc Dis

Clinique Pasteur, 31076 Toulouse, France; CHU de Poitiers, 86021 Poitiers, France; Université de Poitiers, 86073 Poitiers, France; CHU de Grenoble, 38700 La Tronche, France; Centre cardiologique du Nord, 93200 Saint-Denis, France; Paris Cardiovascular Research Centre (Inserm U970), 75015 Paris, France; Maxcure Hospitals, 500081 Hyderabad, Telangana, India; Royal Papworth Hospital NHS Foundation Trust, Cambridge University Health Partners, CB2 0AY Cambridge, UK; Hospital da Luz Arrabida, 4400-346 Vila Nova de Gaia, Portugal; Hopital privé du Confluent, 44000 Nantes, France; Barts Heart Centre, Barts Health NHS Trust, EC1A 7BE London, UK; Hôpital Bichat-Claude-Bernard, 75018 Paris, France; IRSN, 92260 Fontenay aux Roses, France; CHU Haut Lévêque, 33600 Pessac, France; CHU Trousseau, 37170 Chambray-lès-Tours, France; CHRU de Lille, 59000 Lille, France; CHU Pontchaillou, 35033 Rennes, France; CHU Brabois, 54500 Vandœuvre-lès-Nancy, France; Hôpital de La Timone, 13005 Marseille, France; Unité de Rythmologie, Hôpital européen Georges Pompidou, 20-40, rue Leblanc, 75908 Paris cedex 15, France; Paris Descartes University, 75006 Paris, France.

Published: November 2019

This review summarizes the main findings of the French multicentre DAI-PP pilot programme, and discusses the related clinical and research perspectives. This project included retrospectively (2002-2012 period) more than 5000 subjects with structural heart disease who received an implantable cardioverter defibrillator (ICD) for primary prevention of sudden cardiac death, and were followed for a mean period of 3 years. The pilot phase of the DAI-PP programme has provided valuable information on several practical and clinically relevant aspects of primary prevention ICD implantation in the real-world population, which are summarized in this review. This pilot has led to a prospective evaluation that started in May 2018, assessing ICD therapy in primary and secondary prevention in patients with structural and electrical heart diseases, with remote monitoring follow-up using a dedicated platform. This should further enhance our understanding of sudden cardiac death, to eventually optimize the field of preventative actions.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.acvd.2019.05.005DOI Listing

Publication Analysis

Top Keywords

primary prevention
12
sudden cardiac
12
cardiac death
12
implantable cardioverter
8
cardioverter defibrillator
8
therapy primary
8
prevention sudden
8
main findings
8
findings french
8
french multicentre
8

Similar Publications

Exoskeleton Training for Spinal Cord Injury Neuropathic Pain (ExSCIP): Protocol for a Phase 2 Feasibility Randomised Trial.

HRB Open Res

September 2024

UCD School of Public Health, Physiotherapy and Sports Science, Health Sciences Centre, University College Dublin, Dublin, Leinster, Ireland.

Background: Following Spinal Cord Injury (SCI), 53% of people develop neuropathic pain (NP). NP can be more debilitating than other consequences of SCI, and a persistent health issue. Pharmacotherapies are commonly recommended for NP management in SCI, although severe pain often remains refractory to these treatments in many sufferers.

View Article and Find Full Text PDF

Background Diarrhea is defined as three or more loose or watery bowel movements per day and any additional bowel motions that mothers deem abnormal or extra frequent in children. It is important to note that among children in underdeveloped countries, diarrhea is one of the main causes of illness and death. Severe diarrhea causes significant fluid loss and can be fatal.

View Article and Find Full Text PDF

Introduction: The long-term immunogenicity, adverse effects, influencing factors, and protection from booster vaccines remain unclear. Specifically, little is known regarding the humoral immunity and breakthrough infections associated with COVID-19 booster immunization. Therefore, we evaluated the immunogenicity, reactogenicity, influencing factors, and protective effects of the first coronavirus disease booster vaccine 23 months before and after implementation of dynamic zero epidemic control measures among healthcare staff.

View Article and Find Full Text PDF

Introduction: Cardiovascular diseases represent the leading cause of mortality worldwide. This category includes cerebrovascular disease, ischemic heart disease, and peripheral vascular disease. Secondary prevention is effective for patients with a history of cardiovascular events, with antihypertensives, statins, and acetylsalicylic acid being the most prescribed drugs.

View Article and Find Full Text PDF

Objectives: To our knowledge, there is no clear consensus on a definitive cardiac rehabilitation method for patients undergoing Coronary Artery Bypass Graft (CABG). We conducted this systematic review to compare and evaluate the effects of two of the most frequent cardiac rehabilitation modalities, high-intensity interval training (HIIT) and moderate-intensity continuous training (MICT), on cardiopulmonary variables.

Methods: We carried out a systematic search of the databases PubMed, Web of Science, Embase, Scopus, and Google Scholar.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!